Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. - Wikidata - awgldk - TriplyDB

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

http://www.wikidata.org/entity/Q30541002

about

Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond Pathways and therapeutic targets in melanoma Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models Trial watch: Dendritic cell-based anticancer therapy Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).Novel anti-melanoma treatment: focus on immunotherapy.Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus-associated hepatocellular carcinoma.Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19.Messenger RNA (mRNA) nanoparticle tumour vaccination Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex.Melanoma: Advances in Targeted Therapy and Molecular Markers.Cellular immunotherapy of cancer: an overview and future directions.The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition.Transfecting Human Monocytes with RNA.Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.Nuclear Receptor Nur77 Deficiency Alters Dendritic Cell Function

P2860

Q26752558-E6A018A2-118D-428A-9DB7-B881EC808C93 Q26861563-657B695D-029B-4EE0-8455-73521CE5B4B8 Q26865736-0304645D-C2D0-4C2A-BF2A-8B26A3EA53FA Q27012618-9C566EC8-8AB7-472C-8722-ABECB8EE6CD9 Q27024047-F550281C-DB02-40AD-B944-54F398D60522 Q33708572-1FB97945-DE42-436D-9AF9-72997055B905 Q34000700-9865AABC-2D50-4787-A031-031867517715 Q34309404-31989826-A7AC-410A-BE35-4A740A82E918 Q36520189-B21EDE43-F204-468C-BB49-E55A57F98160 Q36583731-29B43455-4D60-495A-AB14-CAAD73BF7CF0 Q36712346-21FAF644-D7FA-4CE1-A9A2-D940A29EB83E Q38218147-29C5C178-CF4B-4F3B-91DE-3C901C2355E0 Q38269935-ECACDDEE-3C48-441A-9D49-2FB006DC1A9B Q38557217-41190AC2-D138-42CD-8C0B-57310F77FE4F Q38673161-35BA2D1D-F776-4C8F-B9CC-70D3344444C8 Q38833090-2BAC589B-1819-4280-ADCF-A9A72DC2991C Q46540870-1EA8C225-9F52-42F3-92A3-8DE249C4932D Q48319918-BA2A6905-7D55-477D-BC5B-41566AB25666 Q58801877-1C4185C5-5F9A-40D9-9FB7-7540F711B39F

P2860

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

http://www.wikidata.org/entity/Q30541002

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

@ast

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

@en

type

label

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

@ast

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

@en

prefLabel

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

@ast

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

@en

P1433

Q30541002-860DAA39-7B4D-4310-AFE4-8FAAC29343E5

P1476

Q30541002-1EE5DE24-7B27-40B8-9919-91D2AD7666CA

P2093

Q30541002-10006F0F-61C7-4BA7-AE55-BBC965798AE7

Q30541002-1DB91B0D-4AB7-4865-A2FE-333AD23B5423

Q30541002-1E4EDCFB-627B-4DE0-832D-8C9F4AE95239

Q30541002-1F7264FD-DFDE-4FC7-AEE9-19FDDFD65E2E

Q30541002-2831C6F5-7667-4A6A-A964-0F9004E0BC00

Q30541002-353C0A9D-0DF1-410A-83B6-2A8AF50E9D97

Q30541002-5421E9B5-C467-424A-9B47-2730BEB78A54

Q30541002-822AAA5F-8D7F-4560-82C1-3AADDB4F491B

Q30541002-9F5F93EE-B1A6-4449-8DB9-BAD0B963FFB6

Q30541002-9FFC8EFB-67E2-4474-80F9-B40768BFC595

P2860

Q30541002-02180887-78C7-4082-9342-25C542E9F1C6

Q30541002-11AD8105-AEBD-4CC5-88C0-FF51ABD8404F

Q30541002-125E9C3F-53F5-4D40-AA78-B5783B59CED5

Q30541002-2DC43AEE-47E8-44B5-AA1D-D7522FFF4F2C

Q30541002-3248A66D-EE45-4581-B8DB-F9F48405322D

Q30541002-46FBB06E-56C1-4B6D-8072-D26A0FB7A5E0

Q30541002-475A4394-2D17-442D-BD88-BB3818083D92

Q30541002-58F906BB-1A64-4549-BB50-9EBA0A1481AB

Q30541002-74C625AC-68F8-4A5B-A009-6950DD0F5309

Q30541002-8ACD678B-E615-4A38-AFA4-32AB0C19CDFD

P304

Q30541002-3BD238F7-017A-4397-A0D8-B03BEE9D6CEA

P31

Q30541002-942D2257-2215-44A6-B8AB-B6D68C6FB731

P356

Q30541002-5EDB4B4F-CEFD-4CD6-AFB7-BD2DAE9613C8

P407

Q30541002-52F71889-4923-44FA-B876-846EC22A8035

P433

Q30541002-7DB5BEE4-61BD-4BA7-9905-E3C6FD7FBFB4

P478

Q30541002-81F211F7-F851-4178-8830-15777C685978

P50

Q30541002-C3A58AF8-B1A2-4C6E-8E43-226016ED3C39

P577

Q30541002-2C7B7433-3231-429C-8194-C1A0319683C6

P698

Q30541002-28D94CA9-6C79-4990-A1A3-37A1EFE0E20C

P921

Q30541002-69B6AE64-2105-4EEF-95D0-F47B02CCA66E

P932

Q30541002-7EA2A931-EA20-45F4-9ECE-0387D7337C99

P356

P1433

Journal of Clinical Investigation

P1476

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome

@en

P2093

David Boczkowski

http://www.w3.org/2001/XMLSchema#string

Douglas S Tyler

http://www.w3.org/2001/XMLSchema#string

Duane A Mitchell

http://www.w3.org/2001/XMLSchema#string

Gary Archer

http://www.w3.org/2001/XMLSchema#string

James Burchette

http://www.w3.org/2001/XMLSchema#string

Jens Dannull

http://www.w3.org/2001/XMLSchema#string

Maria A Selim

http://www.w3.org/2001/XMLSchema#string

Mark Harper

http://www.w3.org/2001/XMLSchema#string

N Rebecca Haley

http://www.w3.org/2001/XMLSchema#string

Nancy Pickett

http://www.w3.org/2001/XMLSchema#string

P2860

Circulating tumor cells: approaches to isolation and characterization

Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity

Dendritic cells and the control of immunity

Cancer immunotherapy via dendritic cells

Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome.

Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells.

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

Circulating tumor cells in breast cancer patients: an evolving role in patient prognosis and disease progression

Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells.

P304

3135-3145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI67544

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23934126

http://www.w3.org/2001/XMLSchema#string

P921

P932

3696565

http://www.w3.org/2001/XMLSchema#string